A Canadian biotech company says it is ready to start commercial production of psilocybin mushrooms. Core One Lab Co., Ltd.is based in Vancouver and “plans to begin commercial production of clinical-grade psilocybin in its Good Manufacturing Practices (GMP) facility in January 2023.” According to Benzinga.
The outlet reported that the company’s chief executive, Joel Schucker, “explained that the company is in the first stages of testing the commercial potential of high-quality psilocybin.”
“We anticipate positive results regarding Core One’s commercial capabilities and the rapid transition of our products to commercialization. It will attract and please our current shareholders.” shucker said.
October, Core One announced Good Manufacturing Practices for psychedelic compounds, as the company is in negotiations with accredited facilities and has detailed plans to provide high-quality, affordable psychedelic drugs to properly licensed clinics and distributors. (GMP) approaching production.
The company said at the time that its goal was to “create pharmaceutical-grade psychedelic products for patients to treat a variety of ailments, including anxiety, depression, addiction, Parkinson’s disease, and other mental health and neurological disorders.” was
“By partnering with GMP production facilities, we start by manufacturing psychedelic compounds and putting them into patient-friendly forms such as capsules. As Core One’s drug pipeline progresses, we plan to create proprietary drug formulations that can be manufactured in these GMP facilities,” the company said in an October announcement. I’m here. “GMP is a pillar of quality assurance processes that seek to ensure that products are manufactured in a consistent manner that meets or exceeds mandated safety and quality standards.”
Benzinga’s Report Along with commencing production of psilocybin next month, CoreOne will “advance the market production of other active pharmaceutical ingredient (API) psychedelic compounds, ultimately manufacturing and distributing them to licensed medical clinics and professionals, researchers, and agents across Canada. We plan to supply it to therapeutic development companies, as well as other countries.”
The company said, Developed and filed a patent Under its subsidiary Acom Biotech, it already holds four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, as well as its subsidiary Awakened Biosciences. has three provisional patents relating to additive synthetic techniques for psilocybin and psilocin production processes under
The company’s move comes at a time when Canadian leaders are revising the laws and regulations surrounding psilocybin. In October, Alberta began regulating the use of psychedelic drugs by people undergoing treatment. This is the first of its kind in a Canadian jurisdiction and a decision that Core One hailed as “groundbreaking.”
“New Alberta regulations require medical directors to apply for a license before treating patients with hallucinogens for mental health disorders. All treatments must be overseen: medical professionals cannot charge for medications, and qualified professionals must administer medications to patients only in medical facilities.”Care”, the company Said in October. “This important step taken by the Canadian government agency is a milestone and we see it as the beginning of a complete paradigm shift in Canada.”